PHARMACEUTICALS

November 2010

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

ADVANTAGE INDIA Pharmaceuticals November 2010

Advantage India
The custom manufacturing outsourcing (CMO) market has recorded a growth rate of approximately 43 per cent, thrice that of the global market rate, during the period 20072010. India has a significant cost advantage over the US. Manufacturing costs in India are approximately 35 to 40 per cent of those in the US due to low installation and manufacturing costs. Indias available talent pool of trained chemists, which is around six times that of the US and works at approximately one-tenth of US manpower costs, also supports this trend.

Preferred outsourcing destination for MNCs

Strong quality and technical capabilities

In 2009, India had more than 120 US Food and Drug Administration (FDA)approved plants and approximately 84 UK Medicines and Healthcare products Regulatory Agency (MHRA)-approved plants, with capabilities to manufacture products with exceptional quality standards.

Government support

Advantage India

Innovative product development

Approval time for a manufacturing facility has been reduced in 2008 to about two weeks Wide product from about three months previously. portfolio In addition, the Government of India (GoI) has set zero duty for technology upgrades and has also set up NIPERs as centres of excellence for pharmaceutical education and research. India accounts for 8 per cent of global pharmaceutical production. Indian firms produce about 60,000 generic brands across 60 therapeutic categories. In addition, Indian firms manufacture approximately 500 different active pharmaceutical ingredients (APIs).
NIPER: National Institute of Pharmaceutical Education and Research Sources: Taking wings, Ernst & Young, 2009; Ernst &Young analysis.

The industry is constantly engaged in upgrading technology to enhance the quality of products. India is expected to be among the worlds top five innovative hubs with contributions of around 50 per cent to drugs discovered worldwide.

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

MARKET OVERVIEW Pharmaceuticals November 2010

Market overview

India is one of the fastest-growing pharmaceutical markets in the world, and its market size has nearly doubled since 2005.
The Indian pharmaceutical market is expected to reach US$ 20 billion by 2015, growing at a compound annual growth rate (CAGR) of 11.7 per cent during 20052015 and establish its presence among the worlds leading 10 markets. It is the third-largest market in the world in terms of volume and fourteenth in terms of value.

Market size of the Indian pharmaceutical industry

25 20 20 US$ billion 15 10 5.75 5 0 2005 2009(F) 2015(F)

11.5

Sources: Taking wings, Ernst & Young, 2009; Indian pharma market valued at over Rs 55K crore in FY10, The Economic Times, 30 July 2009 F: Forecasts

MARKET OVERVIEW Pharmaceuticals November 2010

Market segments
Pharmaceuticals

Contract research and manufacturing services (CRAMS)

India is a fast-growing CMO and custom research outsourcing (CRO) destination with a growth rate for CMO thrice the global market rate.

Formulations
Indias manufacturing prowess in formulations is validated by the fact that it manufactures 60,000 packs across 60 therapy areas.

Active pharmaceutical ingredients (APIs)

India is the third-largest player in the world with 500 different APIs.

Source: Taking wings, Ernst & Young, 2009.

MARKET OVERVIEW Pharmaceuticals November 2010

Exports

Exports of pharmaceutical products have more than doubled over three years to around US$ 5.2 billion in 20092010. The export of drugs, pharmaceuticals and fine chemicals has increased from US$ 7.24 billion in 200708 to around US$ 9.35 billion in 2008 09. This increase can be mainly attributed to increased exports to Africa region, driven by funding support from the Pharmaceutical Export Promotion Council (Pharmexcil) for the brand promotion of the Indian pharmaceutical industry in Africa. In addition, the pharmaceutical sector has been included in market-linked focus product schemes.

Exports of pharmaceutical products

6 5.08 5 US$ billion 4.16 3.18 2.06 2 1 0
2003-2004 2004-2005 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

5.19

4 3 1.62 2.44

Sources: Ministry of Commerce and Industry, Government of India; Ernst & Young analysis; Pharma exports up by 29% in 200809, Anand Sharma addresses Indo-Africa Pharma Business Meet, Ministry of Commerce and Industry press release, http://commerce.nic.in/pressrelease/pressrelease_detail.asp?id=2478, 25 September 2009; UN comtrade data, UN comtrade website, http://comtrade.un.org/db/dqBasicQueryResults.aspx?px=HS&cc=30&r=699&p=0&rg=2&y=2009,2008,2007,2006,2005&so=8 , accessed 10 November 2010. Note: HS code 30 used for the analysis above

MARKET OVERVIEW Pharmaceuticals November 2010

Growth drivers technical capability

US FDA-approved plants

In 2009, India had more than120 US FDAapproved plants in addition to 84 UK MHRAapproved plants. Most of these plants have multiple approvals from regulatory authorities in Canada, Australia, Germany and South Africa. These approved sites aptly demonstrate the ability of Indian companies to deliver quality products worldwide and serve as platforms for CRAMS players.
Source: Taking wings, Ernst & Young, 2009.

US FDA-approved plants
140 120 100 80 60 40 20 0 India Italy China Spain Taiwan Israel Hungary 55 27 25 10 8 5 >120

MARKET OVERVIEW Pharmaceuticals November 2010

Growth drivers cost efficiency

India rates higher than other countries on cost efficiency.
Percentage overall indexed manufacturing cost (US FDA-approved plants)
120

100
100 80-85

Cost index

80 60 35-40 40 20 0 US Europe India

The Indian market has about 8,000 manufacturers, driving the reduction in costs across the life cycle of a product. This is visibly reflected in the manufacturing costs of US FDA-approved plants in India, wherein the costs are 65 per cent lower than that in the US and 50 per cent lower than that in Europe.
Source: Taking wings, Ernst & Young, 2009.

MARKET OVERVIEW Pharmaceuticals November 2010

Growth drivers government support

Objective Key initiatives undertaken The GoI has extended support for the rapid approval of manufacturing and exports of formulations by reducing the approval time for No Objection Certificate (NOC) manufacturer and NOC export license from 12 weeks to 2 weeks. The GoI has extended collaborations with developed countries by signing Memorandum of Understanding (MOUs) with the US FDA, World Health Organisation (WHO), Health Canada and EMEA region (comprising Europe, Middle East and Asia). The GoI is promoting collaboration among industry, academia and government through various programmes such as the New Millennium Indian Technology Leadership (NMITLI) and Drugs and Pharmaceuticals Research Programme (DPRP). The GoI has set up seven NIPERs as institutes of national importance to achieve excellence in pharmaceutical sciences and technologies, education and training. The GoI has also introduced zero duty for technology upgrades in the pharmaceutical sector through the Export Promotion Capital Goods Scheme (EPCG) scheme. The GoI is embarking on a major multi-billion dollar initiative with 50 per cent public funding through a public-private partnership (PPP) model to harness Indias innovation capability. The vision is to catapult India into one of the top five pharmaceutical innovation hubs by 2020, targeting to achieve a global niche with one out of every five to ten drugs discovered worldwide by 2020 originating from India.

Reduction in approval time

Collaborations between industry, academia and the government Focus on specialised pharmaceutical education Duty relief for technology upgrades

Promotion of Indian drug discovery platforms

Sources: Taking wings, Ernst & Young report, 2009; Pharma exports up by 29% in 200809, Anand Sharma addresses Indo-Africa Pharma Business Meet, Ministry of Commerce and Industry press release, http://commerce.nic.in/pressrelease/pressrelease_detail.asp?id=2478, 25 September 2009.

10

MARKET OVERVIEW Pharmaceuticals November 2010

Key trends growing global demand for generics

US$ billion

MNCs are increasingly looking to expand their presence in emerging markets. Growing focus on healthcare reforms and cost reduction has also led many large global pharmaceutical players to rethink their strategies to leverage the growing potential of branded generics and the over-the-counter (OTC) drugs market. Globally, the generics segment is expected to grow to about US$ 140 billion by 2015.

Global generics market

160 140 120 100 80 60 40 20 0 2008 2015 80 140

Healthcare reforms and cost-saving initiatives as well as US$ 150 billion worth of brands going off-patent by 2015 are expected to continue driving this growth.

Sources: Teva investor presentation, Investor Relations, Teva Pharmaceuticals Industries website, www.tevapharm.com, accessed January 28, 2010; Ernst & Young research.

11

MARKET OVERVIEW Pharmaceuticals November 2010

Key trends launch of patented molecules

The advent of the product patent regime in 2005 has instilled confidence in the intellectual property (IP) regime, with the period between 2008 and 2010 witnessing many patented drug launches. With renewed confidence in the IP regime, large pharmaceutical companies are continuing with patented drug launches in India. Global innovators have secured 302 drug patents from the Indian Patent Office as of October 2008, and this number is expected to grow in the next few years. Between 2005 and 2010, the Indian Patent Office has granted 3,488 product patents. While pharmaceutical MNCs already present in India are further consolidating their presence through acquisitions, many MNCs have staged a re-entry after 2005. The share of pharmaceutical MNCs in the domestic pharmaceutical market is estimated to increase to 35 per cent by 2015 from 25 per cent in 2008.

Company Bristol-Myers Squibb (BMS) MSD Pharmaceuticals Pvt Ltd India GSK AstraZeneca Novartis GSK GSK Pfizer J&J Pfizer MSD GSK MSD

Product Onglyza ISENTRESS Cervarix Crestor Galvus Rotarix Infanrix SUTENT Intelence Champix Januvia Tykerb Gardasil

Launch year 2010 2010 2009 2009 2009 2008 2008 2008 2008 2008 2008 2008 2008

Treatment area Diabetes HIV Vaccine against cervical cancer Dyslipidemia Diabetes Vaccine against rotavirus diarrhea Vaccine against diphtheria, tetanus and pertussis Kidney cancer HIV Smoking cessation Diabetes Breast cancer Vaccine against cervical cancer

Source: Ernst & Young analysis. Note: This is an indicative list.

12

MARKET OVERVIEW Pharmaceuticals November 2010

Key trends rural market opportunities

Robust consumption in the rural economy is expected to be the key growth driver for the Indian market. The potential of the rural pharmaceutical market in India has encouraged many MNCs to enhance their focus on this market. The untapped Indian rural market accounts for 45 per cent of the countrys total GDP. Rural India accounts for more than 70 per cent of all Indian households and close to two-fifths of the total consumption pie. A large number of companies are organising their efforts to derive a major portion of their overall sales from this untapped market.
Source: Ernst & Young research.

Rural initiatives

Novartis rural initiative: Arogya Parivar covers 25 million people in more than 18,000 villages. Through this novel for-profit programme, the company aims to create health awareness among rural masses as opposed to the traditional pharmaceutical marketing approach. The company has divided its field operations into 170 independent cells, each covering a radius of approximately 35 km. Every cell is managed by a supervisor with the assistance of health educators. It is estimated that as of end-2009, the company had operationalised 500 cells.

Sanofi-Aventis has launched Prayas, a continuing education programme for rural doctors across India.
GSK has also strengthened its focus on rural outreach and has initiated a pilot project in Uttar Pradesh.

13

MARKET OVERVIEW Pharmaceuticals November 2010

Key players
Leading Indian players by sales (US$ million) Company Cipla Ranbaxy Laboratories Dr Reddy's Laboratories Sun Pharma Lupin Ltd Aurobindo Pharma Piramal Health Cadila Health Matrix Labs Wockhardt Sales in US$ million 1,127.08 944.97 923.47 813.32 993.29 677.54 416.73 381.85 310.06 309.68 Year-end March 2010 December 2009 March 2010 March 2010 March 2010 March 2010 March 2010 March 2010 March 2009 December 2009 Leading foreign players by sales (US$ million) Company GlaxoSmithKline Pharma Aventis Pharma Abbott India Pfizer Novartis India Merck Wyeth Astra Zeneca Pharma Solvay Pharma Sales in US$ million 398.49 207.45 164.60 176.76 130.05 98.56 79.64 80.31 50.36 Year-end December 2009 November 2009 November 2009 March 2010 December 2009 November 2009 December 2009 December 2009 December 2009

Sources: Relevant company websites and annual reports; Ernst & Young research. Note: All revenues were reported in INR.

14

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

15

INDUSTRY INFRASTRUCTURE Pharmaceuticals November 2010

Industry infrastructure SEZs (1/2)

There are 19 dedicated SEZs in India at various stages of development. Functional pharmaceutical SEZs in India include Jawaharlal Nehru Pharma City (JNPC) in Visakhapatnam (Andhra Pradesh), PHARMEZ (Gujarat) developed by Zydus Infrastructure and PhaEZ Park (Gujarat) developed by Cadila Pharma.
Source: SEZ India, www.sezindia.nic.in, accessed 10 November 2010

16

INDUSTRY INFRASTRUCTURE Pharmaceuticals November 2010

Industry infrastructure SEZs (2/2)

Location of pharmaceutical SEZs in India Pharmaceutical SEZ developers Pharmaceutical SEZ developers

Punjab Ranbaxy Laboratories Ltd Gujarat Zydus Finance Ltd CPL Infrastructure Pvt Ltd Dishman Infrastructure Ltd J.B. SEZ Pvt Ltd Maharashtra
Punjab
Mohali

Andhra Pradesh Divis Laboratories Ltd Ramky Pharma City (India) Ltd Hetero Infrastructure SEZ Ltd Andhra Pradesh Industrial Infrastructure Corporation Ltd(APIIC) Dr Reddy's Laboratories Ltd Deccan Infrastructure and Land Holdings Ltd Dr Reddy's Laboratories Ltd Karnataka Karnataka Industrial Areas Development Board Goa Meditab Specialities Pvt Ltd

Gujarat

Ahmedabad Bharuch Aurangabad Medak Srikakulam Visakhapatnam

Maharashtra

Serum Institute of India Ltd Wockhardt Infrastructure Development Ltd Maharashtra Industrial Development Corporation (MIDC) Ajanta Pharma Ltd Navi Mumbai SEZ Pvt Ltd (Kalamboli Pharmaceutical division)

Pune Raigarh Ratnagiri Ponda, Goa

Karnataka
Hassan

Mehbubnagar

Andhra Pradesh

Source: SEZ India, www.sezindia.nic.in, accessed 10 November 2010

17

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

18

INVESTMENTS Pharmaceuticals

November 2010

Investments (1/2)

Nineteen deals were completed in 2010 (as of October 31, 2010). US-based Abbott Laboratories acquired the healthcare solutions business of Piramal Healthcare Ltd, a Mumbai-based manufacturer and wholesaler of prescription pharmaceuticals at a deal value of US$ 3.7 billion.
Deal type Inbound Outbound Domestic Cumulative FDI inflow

M&A scenario details Period: January 1, 2010 to October 31, 2010 No of deals 8 4 7 Deal value (US$ million) 4,587.1 101.22 -

Period: November 2000 to August 2010

Sector Drugs and pharmaceuticals Amount of FDI inflow (US$ million) 1,822.6

Sources: Thomson One Banker, accessed 12 November 2010; Ernst & Young analysis *Abbott completes acquisition of Piramal's Healthcare Solutions business, becomes leading pharmaceutical company in India, Abbott Press release, www.abbott.com/global/url/pressRelease/en_US/60.5:5/Pre ss_Release_0890.htm, 8 September 2010

Source:Fact Sheet On Foreign Direct Investment (FDI), Department of Industrial Policy and Promotion website, www.dipp.nic.in, accessed 29 January 2009.

19

INVESTMENTS Pharmaceuticals

November 2010

Investments (2/2)
Key deals Deal type Inbound Inbound Outbound Outbound Inbound Acquirer Abbott Laboratories Taro Pharma Strides Arcolab Ltd Solvay Pharma India Ltd Hospira, Inc Target Piramal Healthcare Ltd Sun Pharma India Aspen Pharmacare Hldg Ltd Abbott Capital India Ltd Orchid Chemicals Injectible business Total value (US$ million) 3,712.8 332.4 75.0 66.8 400.0 Completion date September 2010 September 2010 July 2010 April 2010 March 2010

Source: Transactions, via Thomson One Banker accessed 12 November 2010. NA: Not available

20

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

21

POLICY AND REGULATORY FRAMEWORK Pharmaceuticals November 2010

Policy and regulatory framework (1/4)

The Central Drug Standard Control Organisation (CDSCO), which falls under the purview of the Ministry of Health and Family Welfare, is the primary regulatory body in India. The Drug Controller General of India (DCGI) presides over the CDSCO and is in charge of the approval of licenses for drugs at both the central and state levels. In January 2005, India introduced the product patent regime in accordance with the TRIPS agreement with an amendment to the Indian Patents Act. Further, in 2008, the introduction of the Drugs and Cosmetics (Amendment) Act 2008 put forth stringent penalties and imprisonment. FDI of up to 100 per cent in drugs and pharmaceuticals is permitted through the automatic route. For licensable drugs and pharmaceuticals manufactured by recombinant DNA technology and specific cell/tissue-targeted formulations, FDI requires prior government approval.
Source: Capping FDI at 40%, Pharmabiz website, www.pharmabiz.com/article/detnews.asp?articleid=58159&sectionid=47, accessed 16 November 2010. TRIPS: Trade-Related Intellectual Property Rights

22

POLICY AND REGULATORY FRAMEWORK Pharmaceuticals November 2010

Policy and regulatory framework (2/4)

The GoI plans to set up a pharmacopeial commission to support ayurveda, yoga and naturopathy, unani, siddha and homoeopathy (AYUSH) through guidelines laid down in the review of the Eleventh Plan. As stated on the National Pharmaceutical Pricing Authority (NPPA) website, the NPPA is responsible for fixing and controlling the prices of 76 bulk drugs under the Essential Commodities Act. The Department of Pharmaceuticals was formed on July 2, 2008, under the Ministry of Chemicals and Fertilisers with the objective of focusing on the development of the pharmaceutical sector in the country and to regulate various activities related to the pricing and availability of medicines at affordable prices, R&D, the protection of intellectual property (IP) rights and international commitments related to the pharmaceutical sector. The GoI has been actively supporting the industry with various measures. It is embarking on a major multi-billion dollar initiative, with 50 per cent public funding through a PPP model, to harness Indias innovation capability.

23

POLICY AND REGULATORY FRAMEWORK Pharmaceuticals November 2010

Policy and regulatory framework (3/4)

Existing
Central Government
Drug Controller-General of India (DCGI)
(expert committees)

Proposed
Central Drug Administration Three joint drug controllers Two deputy drug controllers Six assistant drug controllers 50 drug inspectors Five technical experts One administrative officer One accounts officer Responsibilities Regulatory affairs and environment New drugs and clinical trails Biologicals and biotechnology products Pharmacovigilance Medical devices and diagnostics Imports Organisational services Training and empowerment Quality control affairs Legal and consumer affairs

State Governments
State drug authorities
(State drug controller and food and drug inspectors)

Responsibilities
Licensing and monitoring manufacturing

Legal cell Spurious drug monitoring Pharmacies

24

POLICY AND REGULATORY FRAMEWORK Pharmaceuticals November 2010

Policy and regulatory framework (4/4)

Budget measures

There has been an increase in weighted reduction from 150 to 200 per cent on expenditure incurred on in-house R&D activities and from 125 to 175 per cent on activities outsourced to specific institutions. The Union Budget of 2010 permitted a partial rollback in excise duty from 8 to 10 per cent (to impact raw-material costs).

Policy measures

The DCGI has made the registration of all clinical trials compulsory for trials initiated after June 15, 2009. Previously, the registration of clinical trials by various institutions and companies was voluntary. The DCGI has discontinued the issuance of the WHO-GMP certificate for both pharmaceutical products and plant audits.

The GoI has issued the draft Drugs and Cosmetics (4th Amendment) Rules, 2009, which provides for product licenses for narcotic drugs and psychotropic substances to be issued by the Central Licensing Approval Authority (CLAA), which were previously issued by state licensing authorities.
Source: India Budget 2010. Note: WHO World Health Organisation, GMP Good manufacturing practice

25

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

26

OPPORTUNITIES Pharmaceuticals November 2010

Opportunities R&D
Indian pharmaceutical R&D expenditure Specifics R&D expenditure as a percentage of sales R&D expenditure in absolute terms (US$ million) 200102 1.4 55 2009 2010# 7.5 622

Indian pharmaceutical companies are ascending the value chain with a focus on innovation. By June 2010, the countrys top 20 leading pharmaceutical companies and their subsidiaries had received US FDA approval for 72 ANDAs. Both the industry and the GoI have enhanced the level of investments in R&D capabilities and infrastructure. Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo, was the top R&D spender during 20092010 at US$ 102 million. Few indigenous pharmaceutical companies such as Sun Pharma and Piramal Healthcare have demerged their research divisions to form separate companies in the last few years. Dr Reddys Laboratories NCE Balaglitazone is Indias first indigenously-developed molecule to enter the Phase III trial. The growing R&D pipeline of Indian companies presents significant in-licensing opportunities for global companies.

Number of Abbreviated New Drug Applications (ANDA) approved by US FDA till June 2010 ANDAs Ranbaxy (subsidiary of Daichii Sankyo) Dr Reddy's Glenmark Aurobindo Pharma Matrix Lab ( subsidiary of Marylan) Lupin Sun 5 7 9 7 10 8 7

Source: Taking wings, Ernst & Young 2009; Pharmexcil, http://pharmexcil.org/data/media_files/Pharmabiz2_media_file_1151.pdf , accessed 12 November 2010. Note: # represents top 20 pharmaceutical companies

27

OPPORTUNITIES Pharmaceuticals November 2010

Opportunities contract manufacturing

Pharmaceutical companies preference for outsourcing as a strategic initiative has increased from 43 per cent in 2006 to 57 per cent in 2009. The Indian pharmaceutical manufacturing outsourcing market was valued at US$ 1.1 billion in 2008, and the segment is currently growing at thrice the global market rate. Indias share of the outsourcing market is estimated to grow from 2.8 per cent in 2007 to 5.5 per cent in 2010.The outsourcing market is estimated to grow to US$ 1 billion by 2010. By 2010, the demand for the contract manufacturing of formulations is likely to range between US$ 210 million and US$ 300 million. The demand for APIs and intermediates is expected to amount to US$ 600 million and US$ 700 million, respectively, by 2010.

Percentage increase in outsourcing activities

100% 90% 80% 43 57

70%
Percentage 60% 50% 40% 30% 20% 10% 0% 2006 In-house operations 58

42

2009 MNCs outsourcing

Source: Taking wings, Ernst & Young, 2009

APIs/intermediate outsourcing is more prevalent in India than formulation outsourcing; 64 per cent of total outsourcing is in the area of APIs/intermediates.
28

OPPORTUNITIES Pharmaceuticals November 2010

Opportunities clinical research

The clinical trials market in India, valued at US$ 275 million in 2008 is expected to grow at a CAGR of about 24 per cent during 20082011, nearly double the global average.
Market size forecast for Indian clinical research market (US$ million)
700 608 600 500 400 300 211 200 100 0 2005 2006 2006 2007 2008 2009 F 2010 F 2011F 95 124 161 275 360 468

Source: The glorious metamorphosis, Ernst & Young, 2009.

29

OPPORTUNITIES Pharmaceuticals November 2010

Opportunities biosimilars

The increasing use of biologics in disease areas such as cancer and auto-immune and orphan diseases, in addition to healthcare cost containment, has driven the growth of biosimilars. Companies in this space include Reliance Biopharma, Shantha Biotech, Panacea Biotec, Wockhardt, Dr Reddys, Biocon, Intas Biopharmaceuticals and Avesthagen.
Future opportunity in biosimilars (US$ billion)

23.0

39.0

115.0
76.0 14.0 Patents expired before 2010 Patents expiring 2010-2015 Patents expiring 2016-2020 Biosimilar opportunity-2008 brand value Biosimilar opportunity-2015 brand value

Sources: Teva investor presentation, Teva Pharm website, www.tevapharm.com, accessed 28 January 2010; Ernst & Young research.

30

PHARMACEUTICALS

November 2010

Contents

Advantage India Market overview Industry infrastructure Investments Policy and regulatory framework

Opportunities
Industry associations

31

INDUSTRY ASSOCIATIONS Pharmaceuticals November 2010

Industry associations
The Indian Pharmaceutical Association Kalina, Santacruz (E), Mumbai 400 098 Phone: 91-22-2667 1072 Fax: 91 22 2667 0744 E-mail: ipacentre@ipapharma.org www.ipapharma.org Indian Drug Manufacturers' Association 102-B, Poonam Chambers, Dr A.B. Road Worli, Mumbai 400 018 Phone: 91-22-2494 4624/2497 4308 Bulk Drug Manufacturers Association C-25, Industrial Estate, Sanath Nagar Hyderabad 500018

Organisation of Pharmaceutical Producers of India Peninsula Chambers, Ground Floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Phone: 9122 24918123, 24912486, 66627007 Fax: 9122 24915168 E-mail: indiaoppi@vsnl.com
www.indiaoppi.com

Fax: 9122 24950723

E-mail: idma1@idmaindia.com www.idma-assn.org

Phone: 91 40 23703910/23706718 Fax: 91 40 23704804 E-mail: info@bdmai.org

www.bdmai.org

32

INDUSTRY ASSOCIATIONS Pharmaceuticals November 2010

Note
Wherever applicable, numbers in the report have been rounded off to their nearest whole number. Conversion rate used: US$ 1= INR 48

33

PHARMACEUTICALS

November 2010

DISCLAIMER
India Brand Equity Foundation (IBEF) engaged Ernst & Young Pvt Ltd to prepare this presentation and the same has been prepared by Ernst & Young in consultation with IBEF. All rights reserved. All copyright in this presentation and related works is solely and exclusively owned by IBEF. The same may not be reproduced, wholly or in part in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this presentation), modified or in any manner communicated to any third party except with the written approval of IBEF. This presentation is for information purposes only. While due care has been taken during the compilation of this presentation to ensure that the information is accurate to the best of Ernst & Young and IBEFs knowledge and belief, the content is not to be construed in any manner whatsoever as a substitute for professional advice. Ernst & Young and IBEF neither recommend nor endorse any specific products or services that may have been mentioned in this presentation and nor do they assume any liability or responsibility for the outcome of decisions taken as a result of any reliance placed on this presentation. Neither Ernst & Young nor IBEF shall be liable for any direct or indirect damages that may arise due to any act or omission on the part of the user due to any reliance placed or guidance taken from any portion of this presentation.

34